Abstract
Background and objective
Benralizumab (Fasenra™) has recently been approved as add-on maintenance treatment for adult patients with severe eosinophilic asthma inadequately controlled despite high-dosage inhaled corticosteroids plus long-acting β2-agonists. We aimed to identify and describe the clinical characteristics and disease burden of patients with severe, uncontrolled, eosinophilic asthma in France who may be eligible for treatment with benralizumab.
Patients and methods
This was a retrospective analysis of a prospective, noninterventional, observational study of patients in France enrolled in the Asthma and Bronchial Obstruction Cohort (COBRA). First, we selected adult patients with severe asthma, a documented blood eosinophil count, 12 months of baseline data, and 12 months of follow-up data. Of these study-eligible patients, we next determined the prevalence and described the clinical characteristics and disease burden of patients who would be eligible to receive benralizumab, namely those with ≥2 asthma exacerbations in the previous 12 months and a blood eosinophil count ≥300/μL who were receiving high-dosage inhaled corticosteroids/long-acting β2-agonists.
Results
Of the 441 patients eligible for this study, 85 (19%) met the criteria for benralizumab therapy. At study inclusion, benralizumab-eligible patients had a smaller prebronchodilator forced expiratory volume in 1 second and less effective asthma control compared with benralizumab-ineligible patients. During the 12-month follow-up period, benralizumab-eligible patients had greater frequencies of asthma exacerbations and hospitalizations compared with benralizumab-ineligible patients.
Conclusion
Of patients with severe asthma, approximately 20% were qualified for benralizumab treatment. Benralizumab-eligible patients had increased bronchial obstruction, worse asthma control, and a greater frequency of asthma exacerbations and hospitalizations during follow-up care compared with benralizumab-ineligible patients, demonstrating inadequate disease control for these patients.
Keywords: COBRA, benralizumab, biologic, eosinophilia, France
Introduction
France has one of the highest prevalences of asthma worldwide, approaching 7% in the adult population.1,2 Up to 10% of adult patients with asthma have severe asthma, which require treatment with high-dosage inhaled corticosteroids (ICS) plus long-acting β2-agonists (LABA) to control their disease.3 A further subset of patients has uncontrolled asthma symptoms despite these treatments. These uncontrolled symptoms, which place patients at high risk for asthma exacerbations, hospitalizations, and diminished health-related quality of life, are associated with significant health care costs.4 The annual cost of severe asthma rises with decreasing asthma control and can reach €2,000 per patient year in France.5
Additional therapeutics are needed to control severe asthma for patients who do not respond well to conventional anti-inflammatory treatment. Targeted therapeutics are effective add-on treatments, particularly when patients are selected using appropriate biomarkers (eg, high blood eosinophil counts).6 Eosinophilia is associated with asthma severity and poor asthma control.7–9 Benralizumab is a humanized, afucosylated IL-5 receptor alpha–directed cytolytic monoclonal antibody that induces direct, rapid, and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity.10 In phase III trials (SIROCCO [NCT01928771] and CALIMA [NCT01914757]), benralizumab in combination with high-dosage ICS/LABA significantly reduced annual asthma exacerbation rates and improved lung function and asthma control for patients with severe, uncontrolled asthma with eosinophilia.11,12 In the EU, benralizumab (Fasenra™, AstraZeneca AB, Södertälje, Sweden) is indicated for add-on maintenance treatment of adult patients with severe eosinophilic asthma inadequately controlled despite high-dosage ICS/LABA.13
The objectives of this study were to determine the prevalence and describe the clinical characteristics and disease burden of adult patients in France with severe, uncontrolled asthma who may be eligible for benralizumab treatment based on SIROCCO/CALIMA enrollment (high-dosage ICS/LABA, ≥2 asthma exacerbations in the prior 12 months) and stratification criteria (blood eosinophil counts ≥300 cells/μL). Patients eligible for this study were derived from the Asthma and Bronchial Obstruction Cohort (COBRA), a French multi-center, prospective cohort of patients that includes those with COPD and approximately 1,000 patients with asthma.14,15
Material and methods
Study design and participants
This study was a retrospective analysis of the COBRA study, an ongoing French multicenter, prospective, noninterven tional, observational study of adult patients (≥18–80 years old) with either asthma or COPD with 10 years of followup.14,15 A detailed description of the COBRA study design has been published.15 Patients were enrolled into COBRA regardless of disease severity. Data and biological sample collection began in March 2008.
Data extraction for this study occurred on December 9, 2015. To be eligible for this retrospective study, patients in COBRA were required to have severe asthma (defined as requiring Global Initiative for Asthma [GINA] step 4 or 5 treatment), documented blood eosinophil counts, and at least 12 months of follow-up data (Figure 1). Study-eligible patients were considered for benralizumab treatment if they were receiving high-dosage ICS/LABA, had experienced ≥2 asthma exacerbations that required treatment with systemic corticosteroids in the year prior to the index date, and had blood eosinophil counts ≥300 cells/μL (Figure 1).
Figure 1.
Eligibility criteria and study design.
Abbreviations: COBRA, Asthma and Bronchial Obstruction Cohort; GINA, Global Initiative for Asthma; ICS, inhaled corticosteroids; LABA, long-acting β2-agonists.
Baseline data for patient characterization were collected for one year prior to the index date (visit 1; Figure 1) and included patient demographics, comorbidities, treatment, asthma severity, asthma exacerbations, emergency department visits, and hospitalizations. Blood eosinophil counts were obtained at and after the index date. One year of outcome data after the index date was extracted as well.
Outcomes
The objectives of this analysis were to determine the prevalence and describe the clinical characteristics and disease burden of patients with severe asthma in the COBRA cohort who were eligible for benralizumab treatment based on SIROCCO/CALIMA enrollment and stratification criteria. Endpoints to describe disease burden were the number of asthma exacerbations, asthma-related emergency department visits, and asthma-related hospitalizations during the 12-month period post index date. Asthma exacerbations were defined as a worsening of asthma requiring the use of systemic corticosteroids (or a temporary increase in a stable oral corticosteroid background dose) for at least three days. The level of asthma control was assessed by the Asthma Control Questionnaire (ACQ). Optimal asthma control was defined as ACQ scores ≤0.5, suboptimal asthma control as scores >0.5–1.5, and unacceptable asthma control as scores >1.5.15
Statistical analysis
Data were entered in the COBRA database using an electronic case report form. Stata® software (StataCorp LLC, College Station, TX, USA), version 13.1, and R software, version 2.15.2 (The R Foundation for Statistical Computing, Vienna, Austria), were used for data management and data analysis, respectively. Continuous variables were summarized with descriptive statistics (number, mean, SD, range, and median), and frequency counts and percentages within each category were provided for categorical data. Asthma exacerbations and hospitalizations were expressed as rates (number per year) and as percentage of patients having at least one event. Emergency department visits were expressed as the percentage of patients having at least one emergency department visit during follow-up. Estimates for one year of follow-up were derived from visits that occurred during the 9–15-month interval range, with rates annualized. When possible, missing data were obtained from the patients’ medical records. Statistics were computed for patients with available (nonmissing) data. No imputation was performed. Characteristics of patients eligible for benralizumab treatment were compared with those of benralizumab-ineligible patients using nonparametric tests: Fisher’s exact test and Mann–Whitney U test for categorical and continuous variables, respectively. Asthma exacerbation rates were analyzed by Poisson regression models with the logarithm of follow-up as an offset variable. Differences between groups were considered statistically significant if P-values were <0.05. No attempt was made to adjust for multiple comparisons.
Ethics approval and informed consent
The COBRA study was approved by the Comités de Protection des Personnes Ile-de-France I (number 09-11962), and all patients gave their written informed consent before being enrolled.
Results
Of 1,081 patients in the COBRA database, 441 patients recruited from nine hospitals fulfilled the study inclusion criteria of having severe asthma, at least one year of followup data, and documented blood eosinophil counts (Table 1). During the year prior to the index date, 230 (52%) of the 441 patients experienced ≥2 asthma exacerbations that required treatment with systemic corticosteroids, 187 patients (42%) also received high-dosage ICS/LABA, and 85 patients (19%) also had blood eosinophil counts ≥300 cells/μL. Thus, 19% of adult patients with severe asthma in the COBRA study met the eligibility criteria for benralizumab therapy.
Table 1.
Characteristics of the study sample (N=441)
| Criteria | No n (%) |
Yes n (%) |
|---|---|---|
| ≥2 asthma exacerbations in previous 12 months | 211 (48) | 230 (52) |
| Eosinophil count ≥300 cells/µL | 267 (61) | 174 (40) |
| High-dosage ICS/LABA | 118 (27) | 323 (73) |
| All three criteria together (benralizumab eligibility) | 356 (81) | 85 (19) |
| High-dosage ICS/LABA AND ≥2 asthma exacerbations in previous 12 months | 254 (58) | 187 (42) |
| High-dosage ICS/LABA AND ≥2 asthma exacerbations in previous 12 months AND | ||
| Eosinophil count ≥100 cells/µL | 292 (66) | 149 (34) |
| Eosinophil count ≥150 cells/µL | 312 (71) | 129 (29) |
| Eosinophil count ≥300 cells/µL | 356 (81) | 85 (19) |
| Eosinophil count ≥400 cells/µL | 379 (86) | 62 (14) |
Abbreviations: ICS, inhaled corticosteroids; LABA, long-acting β2-agonists.
Patient demographics were similar between benralizumab-eligible and -ineligible patients and were representative of patients with severe asthma (Table 2). The median ages for benralizumab-eligible and -ineligible patients were 50 years and 53 years, respectively (P=0.10). Most patients were white (benralizumab-eligible patients: 74%, benralizumab-ineligible patients: 81%), and more than half of the patients in each group were female (benralizumab-eligible patients: 67%, benralizumab-ineligible patients: 68%; P=0.90). Mean predicted prebronchodilator forced expiratory volume in 1 second (FEV1) was smaller for ben-ralizumab-eligible patients than for benralizumab-ineligible patients (70% vs 76%, respectively; P=0.03; Table 3).
Table 2.
Demographics and baseline clinical characteristics of COBRA patients with severe asthma at study inclusion
| Demographics and baseline clinical characteristics | Benralizumab-ineligible patients (n=356) | Benralizumab-eligible patients (n=85) | P-value |
|---|---|---|---|
| Median age, years (IQR) | 53 (40–62) | 50 (40–57) | 0.10 |
| Female, n (%) | 241 (68) | 57 (67) | 0.90 |
| Mean body mass index, kg/m2 (SD) | 27.3 (6.1) | 26.7 (5.9) | 0.24 |
| Smoking habits, n (%) | |||
| Current smoker | 33 (9) | 2 (2) | 0.08 |
| Past smoker | 104 (29) | 25 (29) | |
| Never-smoker | 218 (61) | 58 (68) | |
| Median smoking history, pack-years (IQR) | 10.0 (5.0–20.0) | 5.5 (5.0–13.8) | 0.40 |
| Median age at asthma onset, years (IQR) | 20 (6–40) | 29 (17–43) | 0.007 |
| Median duration of asthma disease, years (IQR) | 26 (16–41) | 16 (7–28) | <0.001 |
| Number of asthma-related hospitalizations | |||
| Lifetime, mean (SD), median (IQR) | 4.0 (10.0), 1.0 (0.0–4.0) | 4.7 (7.2), 2.0 (0.0–5.0) | 0.01 |
| Previous 12 months, mean (SD), median (IQR) | 0.4 (1.0), 0.0 (0.0–0.0) | 1.2 (6.5), 0.0 (0.0–1.0) | 0.17 |
| Lifetime history of asthma-related ICU hospitalizations, n (%) | 94 (26) | 27 (32) | 0.35 |
| Previous 12-month history of emergency department visits, n (%) | 171 (48) | 56 (66) | 0.004 |
| Frequency of asthma attacks,a n (%) | |||
| None | 96 (27) | 14 (17) | 0.02 |
| <1/month | 102 (29) | 17 (20) | |
| <1/week | 30 (9) | 10 (12) | |
| Several times a week | 71 (20) | 23 (27) | |
| Daily | 53 (15) | 21 (25) | |
| Previous 12-month history of asthma exacerbations, n (%) | 199 (56) | 85 (100)a | <0.001 |
| Number of asthma exacerbations in previous 12 months, | |||
| Mean (SD), median (IQR) | 2.7 (4.0), 1.0 (0.0–4.0) | 6.9 (4.1), 6.0 (3.0–10.0) | <0.001 |
| 0, n (%) | 157 (44) | 0 (0) | <0.001 |
| 1, n (%) | 54 (15) | 0 (0) | |
| 2, n (%) | 26 (7) | 12 (14) | |
| ≥3, n (%) | 119 (33) | 73 (86) | |
| Median duration of asthma exacerbations, days (IQR) | 7.0 (5.0–10.0) | 8.0 (5.0–10.0) | 0.19 |
| Level of asthma control, n (%) | |||
| Optimal | 81 (23) | 4 (5) | <0.001 |
| Suboptimal | 107 (30) | 10 (12) | |
| Not optimal | 164 (47) | 71 (84) |
Notes:
Inclusion criterion.
Abbreviations: COBRA, Asthma and Bronchial Obstruction Cohort; ICU, intensive care unit; IQR, interquartile range.
Table 3.
Pulmonary function tests for patients with severe asthma at study inclusion
| Pulmonary function tests | Benralizumab-ineligible patients (n=356) | Benralizumab-eligible patients (n=85) | P-value |
|---|---|---|---|
| Mean FEV1 before BD, L (SD) | 2.11 (0.81) | 1.99 (0.61) | 0.34 |
| Mean predicted FEV1 before BD, % (SD) | 76 (24) | 70 (18) | 0.03 |
| Mean FEV1/FVC, % (SD) | 66 (13) | 65 (13) | 0.24 |
| Reversibilitya [yes], n (%) | 53 (19) | 21 (30) | 0.05 |
Notes:
Reversibility of FEV1 was defined as an increase of ≥0.20 L and of 12%.
Abbreviations: BD, bronchodilator; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
At study inclusion, benralizumab-eligible patients had less effective asthma control than benralizumab-ineligible patients (optimal in 5% of patients vs 23% of patients, respectively; P<0.001; Table 2). Benralizumab-eligible patients had a higher mean number of asthma exacerbations in the previous 12 months compared with benralizumab-ineligible patients (6.9 vs 2.7, respectively; P<0.001; Table 2). The percentage of benralizumab-eligible patients who experienced asthma “attacks” (interpreted by patients as an asthma crisis) was greater than that of benralizumab-ineligible patients (Table 2; P=0.02).
Benralizumab-eligible patients had a greater prevalence of nasal polyposis (42% vs 22%; P=0.003), greater use of ICS/LABA/long-acting muscarinic antagonists (LAMA) (21% vs 12%; P=0.03) and antileukotriene agents (47% vs 31%; P=0.01). Both LAMA (21% vs 13%; P=0.06) and oral corticosteroid (27% vs 19%; P=0.13) use by benralizumab-eligible patients were greater than benralizumab-ineligible patients but these differences did not reach statistical significance (Table 4). At study inclusion, 6 (7%) benralizumab-eligible patients and 28 (8%) benralizumab-ineligible patients were receiving omalizumab (P=1; Table 4). During the one-year follow-up period, these numbers increased to 48 (57%) and 104 (29%) patients in the benralizumab-eligible and -ineligible groups, respectively (P=0.01).
Table 4.
Allergy-related comorbidities and asthma treatments at study inclusion
| Comorbidities and asthma treatments | Benralizumab-ineligible patients (n=356) |
Benralizumab-eligible patients (n=85) |
P-value |
|---|---|---|---|
| Allergy-related comorbidities, n (%) | |||
| Sinusitis | 117 (33) | 34 (40) | 0.25 |
| History of sinus surgery | 50 (14) | 21 (25) | 0.02 |
| Nasal polyposis | 79 (22) | 36 (42) | 0.003 |
| Allergic rhinitis | 237 (67) | 53 (62) | 0.44 |
| Conjunctivitis | 124 (35) | 18 (21) | 0.01 |
| Eczema | 87 (24) | 19 (22) | 0.78 |
| Urticaria | 62 (17) | 13 (15) | 0.75 |
| Positive skin tests | |||
| Pollens | 95 (35) | 17 (25) | 0.11 |
| House dust mites | 129 (48) | 24 (35) | 0.06 |
| Alternaria | 31 (12) | 3 (4) | 0.11 |
| Aspergillus | 22 (9) | 1 (2) | 0.06 |
| Cladosporium | 12 (5) | 0 (0) | 0.08 |
| SABA, n (%) | 332 (94) | 82 (97) | 0.44 |
| LABA, n (%) | 342 (97) | 85 (100) | 0.08 |
| ICS, n (%) | 350 (98) | 85 (100) | 0.60 |
| LAMA, n (%) | 46 (13) | 18 (21) | 0.06 |
| ICS/LABA, n (%) | 342 (96) | 85 (100) | 0.08 |
| ICS/LABA/LAMA,a n (%) | 42 (12) | 18 (21) | 0.03 |
| Median daily dosage of ICS,b µg (range) | 2,000 (1,000–2,000) | 2,000 (1,500–8,000) | <0.001 |
| Oral corticosteroids, n (%) | 67 (19) | 23 (27) | 0.13 |
| Median daily dosage of OCS,b mg (range) | 20.0 (15.0–40.0) | 20.0 (2.0–80.0) | 0.7 |
| Antileukotriene agents, n (%) | 110 (31) | 39 (47) | 0.01 |
| Theophylline, n (%) | 13 (4) | 3 (4) | 1 |
| Anti-IgE (omalizumab), n (%) | 28 (8) | 6 (7) | 1 |
Notes:
Patients receiving ICS/LABA/LAMA are represented in the ICS/LABA, ICS, LABA, and LAMA categories as well.
Computed for patients who received corticosteroids.
Abbreviations: ICS, inhaled corticosteroids; IgE, immunoglobulin E; LABA, long-acting β2-agonists; LAMA, long-acting muscarinic antagonist; OCS, oral corticosteroids; SABA, short-acting β2-agonists.
For the 12-month follow-up period, data were missing for 22 (26%) benralizumab-eligible patients and 90 (25%) benralizumab-ineligible patients for the number of asthma exacerbations, asthma-related visits to emergency departments, and hospitalizations. Mean (range) follow-up periods for benralizumab-eligible and -ineligible patients were 364 (274–455) days and 374 (277–456) days, respectively (P=0.11). Benralizumab-eligible patients had a greater mean incidence of asthma exacerbations (3.9/year vs 2.2/year; P<0.001) and asthma-related hospitalizations (0.19/year vs 0.09/year; P=0.02) compared with benralizumab-ineligible patients (Table 5 and Figure 2). The percentage of benralizumab-eligible patients who visited the emergency department was greater than that of benralizumab-ineligible patients (40% vs 25%; P=0.03; Table 5). Median blood eosinophil counts remained greater than 300 cells/μL for benralizumab-eligible patients throughout the 12-month follow-up period (Table 6).
Table 5.
Asthma exacerbations, emergency department visits, and hospitalizations during 12-month follow-up period
| Asthma exacerbations, emergency department visits, and hospitalizations | Benralizumab-ineligible patients (n=266) | Benralizumab-eligible patients (n=63) | P-value |
|---|---|---|---|
| ≥1 emergency department visit, n (%) | 67 (25) | 25 (40) | 0.03 |
| Asthma-related hospitalizations, n/yeara | |||
| Mean (SD), median (IQR) | 0.09 (0.42), 0 (0–0) | 0.19 (0.66), 0 (0–0) | 0.02 |
| ≥1, n (%) | 15 (5.6) | 7 (11.1) | 0.16 |
| ≥2, n (%) | 7 (2.6) | 3 (4.8) | 0.41 |
| Asthma exacerbations, n/yeara | |||
| Mean (SD), median (IQR) | 2.2 (5.5), 0 (0–1.9) | 3.9 (8.6), 1.9 (0.8–4.2) | <0.001 |
| ≥1, n (%) | 121 (45.5) | 48 (76.2) | <0.001 |
| ≥2, n (%) | 78 (29.3) | 34 (54.0) | <0.001 |
| ≥3, n (%) | 51 (19.2) | 26 (41.3) | <0.001 |
| ≥4, n (%) | 40 (15.0) | 20 (31.7) | <0.003 |
Notes:
Hospitalization and asthma exacerbation frequencies equal the number of hospitalizations and exacerbations during follow-up divided by the length of follow-up.
Abbreviation: IQR, interquartile range.
Figure 2.
Number of asthma exacerbations in a 12-month period before (inclusion) and 12-month period after (follow-up) index date for benralizumab-ineligible and benralizumab-eligible patients.
Table 6.
Eosinophil counts during 12-month follow-up period for patients with a baseline eosinophil count of ≥300 cells/µL
| Eosinophils at baseline ≥300/µL | Eosinophils (cells/µL)
|
||
|---|---|---|---|
| Visit 1 | Visit 2 | Visit 3 | |
| Benralizumab-ineligible patients,a median (IQR) | 480 (375–750) | 390 (260–595) | 369 (260–680) |
| Benralizumab-eligible patients,b median (IQR) | 490 (390–710) | 390 (233–670) | 340 (190–420) |
Notes:
n=174.
n=85.
Abbreviation: IQR, interquartile range.
Discussion
This retrospective analysis of adult patients with asthma in France enrolled in the COBRA study characterized patients who would potentially be eligible for benralizumab treatment. Based on the eligibility criteria that were used for the SIROCCO and CALIMA phase III randomized controlled trials,11,12 approximately 20% of patients with severe asthma in this analysis were eligible for benralizumab treatment. In SIROCCO and CALIMA, eligibility criteria included a baseline blood eosinophil count of ≥300 cells/μL. In a post-hoc analysis of benralizumab-responsive patients in SIROCCO/CALIMA,16,17 benralizumab improved lung function and total asthma symptom score and decreased annual asthma exacerbation rate compared with placebo for patients with blood eosinophil counts ≥150 cells/μL. If a blood eosinophil count of ≥150 cells/μL at study inclusion had been used in this analysis of COBRA patients, the benralizumab-eligible population would have increased to 29%. Oral corticosteroids decrease blood eosinophil counts.18 In the ZONDA trial,19 benralizumab was shown to be efficacious in patients with severe asthma receiving high-dosage ICS/LABA and oral corticosteroids, and with blood eosinophil counts ≥150 cells/μL. If we had expanded the benralizumab-eligibility criteria in the current study to include patients who were receiving oral corticosteroids and had blood eosinophil counts of ≥150 cells/μL, we also would have captured a larger benralizumab-eligible population.
COBRA is a 10-year prospective, noninterventional, observational study that began in 2008. Treatments recommended for asthma in 2008 (eg, medium- or high-dosage ICS/LABA, leukotriene modifiers and sustained-release theophylline, GINA step 4 regimens, and low-dosage oral glucocorticosteroids and anti-immunoglobulin E [IgE] treatments as GINA step 5 regimens) are still widely used and recommended today.20 In recent years, biologics such as anti–IL-5 antibodies have been added to this repertoire.21 At study inclusion and during the 12-month observation period in our study, benralizumab-eligible patients had a greater frequency of hospitalizations, emergency department visits, and asthma exacerbations compared with the general population of study-eligible patients. The frequency of asthma attacks was also greater for benralizumab-eligible patients at study inclusion compared with study-eligible patients. It is clear new therapeutics to improve disease control for patients with severe, eosinophilic asthma are needed.
In addition to benralizumab, there are currently three biologics approved in Europe for the treatment of asthma. Omalizumab (Genentech Inc., South San Francisco, CA, USA) is a humanized anti-IgE monoclonal antibody approved as add-on therapy for patients ≥6 years of age with severe persistent, uncontrolled asthma and either a positive skin test or in-vitro reactivity to a perennial aeroallergen.22 Mepolizumab and reslizumab are anti–IL-5 monoclonal antibodies approved as add-on maintenance treatment for patients with severe asthma and an eosinophilic phenotype.23,24 In the observational, cross-sectional IDEAL study of patients with severe asthma from six countries in Australia, Europe (including France), and North America, 20% of patients were eligible for mepolizumab, 5% for reslizumab, and 31–41% for omalizumab.25 For mepolizumab and reslizumab, eligibility requirements included ≥2 (mepolizumab) or ≥1 (reslizumab) asthma exacerbations requiring oral corticosteroids, emergency department visits, or hospitalizations in the previous 12 months, and blood eosinophil counts of ≥150 cells/μL at study visit or ≥300 cells/μL in the previous 12 months (mepolizumab) or ≥400 cells/μL (reslizumab). Omalizumab qualification criteria included a threshold asthma exacerbation frequency (≥1 or ≥2), high IgE concentrations, and positive allergy test. The percentage of patients with severe asthma enrolled in the COBRA study who would be eligible for benralizumab is consistent with those observed for mepolizumab and reslizumab.
This study had certain limitations. First, the study was not a random sampling of patients with severe asthma in France, for the enrollment process involved pulmonologists in specialized university hospitals. Second, the study took place before the approval of mepolizumab and reslizumab, so we could not undertake an analysis of patients who were treated with these agents and were also eligible for benralizumab treatment. Third, we did not analyze patients treated with omalizumab because the duration of treatment and reasons for cessation were not recorded in the case report forms. Fourth, approximately 25% of patients had missing data on disease burden during the look-forward period.
Conclusion
Approximately 20% of patients in this real-life cohort study were eligible for treatment with benralizumab, a novel agent for the treatment of uncontrolled, severe, eosinophilic asthma. These patients had more frequent asthma exacerbations and symptoms and worse asthma control than the benralizumab-ineligible population of patients with severe asthma. Understanding prevalence and clinic characteristics of patients who would be responsive to benralizumab will be important for clinicians in their decisions to treat severe, uncontrolled asthma with an eosinophilic phenotype.
Data sharing statement
The research protocol developed for this study and data for this retrospective analysis are available upon request from the corresponding author.
Acknowledgments
Editorial support was provided by Francis J Golder, BVSc, PhD, of JK Associates, Inc., and Michael A Nissen, ELS, of AstraZeneca. This study was funded by AstraZeneca.
Footnotes
Author contributions
All authors contributed to the study design, data analysis and interpretation, and preparation of this manuscript and agree to be accountable for all aspects of the work.
Disclosure
Michel Aubier received research grants from AstraZeneca to conduct the study. Gabriel Thabut and Caroline Fabry-Vendrand are employees of AstraZeneca. The authors report no other conflicts of interest in this work.
References
- 1.Delmas MC, Fuhrman C, for the Epidemiology and Research Group SPLF Clinic Asthma in France: a review of descriptive epidemiological data. Rev Mal Respir. 2010;27(2):151–159. doi: 10.1016/j.rmr.2009.09.001. French. [DOI] [PubMed] [Google Scholar]
- 2.To T, Stanojevic S, Moores G, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012;12:204. doi: 10.1186/1471-2458-12-204. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi: 10.1183/09031936.00202013. [DOI] [PubMed] [Google Scholar]
- 4.Peters SP, Ferguson G, Deniz Y, Reisner C. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med. 2006;100(7):1139–1151. doi: 10.1016/j.rmed.2006.03.031. [DOI] [PubMed] [Google Scholar]
- 5.Gadenne S, Pribil C, Chouaid C, Vergnenegre A, Detournay B. Le coût de l’asthme en France et les implications économiques du niveau de contrôle [The costs of asthma in France and the economic implications of its level of control] Rev Mal Respir. 2011;28(4):419–426. doi: 10.1016/j.rmr.2010.11.001. French. [DOI] [PubMed] [Google Scholar]
- 6.Durham AL, Caramori G, Chung KF, Adcock IM. Targeted anti-inflammatory therapeutics in asthma and chronic obstructive lung disease. Transl Res. 2016;167(1):192–203. doi: 10.1016/j.trsl.2015.08.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Price D, Wilson AM, Chisholm A, et al. Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice. J Asthma Allergy. 2016;9:1–12. doi: 10.2147/JAA.S97973. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Talini D, Novelli F, Bacci E, et al. Sputum eosinophilia is a determinant of FEV1 decline in occupational asthma: results of an observational study. BMJ Open. 2015;5(1):e005748. doi: 10.1136/bmjopen-2014-005748. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Belda J, Parameswaran K, Lemière C, Kamada D, O’Byrne PM, Hargreave FE. Predictors of loss of asthma control induced by corticosteroid withdrawal. Can Respir J. 2006;13(3):129–133. doi: 10.1155/2006/189127. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125(6):1344–1353. doi: 10.1016/j.jaci.2010.04.004. [DOI] [PubMed] [Google Scholar]
- 11.FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141. doi: 10.1016/S0140-6736(16)31322-8. [DOI] [PubMed] [Google Scholar]
- 12.Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127. doi: 10.1016/S0140-6736(16)31324-1. [DOI] [PubMed] [Google Scholar]
- 13.Fasenra™. (benralizumab) Summary of product characteristics. [Accessed April 5, 2018]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004433/WC500245331.pdf.
- 14.Epidemiologie—France Portal COBRA—Asthma and Airway Obstruction Cohort: Clinicobiological Cohort Follow-up. 2014. [Accessed October 12, 2017]. Available from: https://epidemiologie-France.aviesan.fr/en/epidemiology/records/asthma-and-airway-obstruction-cohort-clinicobiological-cohort-follow-up.
- 15.Pretolani M, Soussan D, Poirier I, Thabut G, Aubier M, on behalf of the COBRA Study Group Clinical and biological characteristics of the French COBRA cohort of adult subjects with asthma. Eur Respir J. 2017;50(2):1700019. doi: 10.1183/13993003.00019-2017. [DOI] [PubMed] [Google Scholar]
- 16.FitzGerald JM, Bleecker ER, Menzies-Gow A, et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med. 2018;6(1):51–64. doi: 10.1016/S2213-2600(17)30344-2. [DOI] [PubMed] [Google Scholar]
- 17.Goldman M, Hirsch I, Zangrilli JG, Newbold P, Xu X. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies. Curr Med Res Opin. 2017;33(9):1605–1613. doi: 10.1080/03007995.2017.1347091. [DOI] [PubMed] [Google Scholar]
- 18.Austin D, Pouliquen I, Keene O, Yancey S. Blood eosinophil dose response to oral corticosteroids in a population of patients with severe asthma. Eur Respir J. 2016;48:PA1110. [Google Scholar]
- 19.Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid–sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448–2458. doi: 10.1056/NEJMoa1703501. [DOI] [PubMed] [Google Scholar]
- 20.Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31(1):143–178. doi: 10.1183/09031936.00138707. [DOI] [PubMed] [Google Scholar]
- 21.Global Initiative for Asthma Global strategy for asthma management and prevention. 2017. [Accessed October 12, 2017]. Available from: http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention/
- 22.Xolair®. (omalizumab) Summary of product characteristics. [Accessed October 12, 2017]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000606/WC500057298.pdf.
- 23.Nucala®. (mepolizumab) Summary of product characteristics. [Accessed October 12, 2017]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003860/WC500198037.pdf.
- 24.CINQAERO®. (reslizumab) Summary of product characteristics. [Accessed October 12, 2017]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003912/WC500212250.pdf.
- 25.Albers FC, Müllerová H, Gunsoy NB, et al. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study. J Asthma. 2018;55(2):1–9. doi: 10.1080/02770903.2017.1322611. [DOI] [PubMed] [Google Scholar]